TGM2 and glomerulosclerosis: Use of irreversible small molecule TG2 inhibitors in a rat diabetic nephropathy model showed that TG2 inhibition led to reduced glomerulosclerosis and tubulointerstitial fibrosis by up to 77% and 92%, respectively (Johnson et al. 2007).